Unravelling eribulin’s role in metastatic breast cancer: evaluating benefits for both triple negative and non-triple negative patients in real-world scenarios in resource-constrained settings

HIGHLIGHTS

• What: Since the patients were treated with standard institutional protocol and there was no direct contact between the researcher and the patients for the purpose of this study, the need for informed consent was waived. The study provides the largest real-world Indian data of 107 patients with a relatively younger cohort (median age of 52 years) who were heavily pre-treated with median lines of therapy 3 .
• Who: Eribulin et al. from the Department of Medical Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.